Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacogenetic-Guided Antidepressant Prescribing in Adolescents With Anxiety and Depression
Sponsor: University of Calgary
Summary
This is a parallel arm randomized (1:1) controlled trial. Adolescents aged 12-17 years (n=452) who are starting or changing a selective serotonin reuptake inhibitor (SSRI) for depression and/or anxiety will be randomly allocated to receive 12-weeks of pharmacogenetic-guided antidepressant therapy (experimental intervention) or current prescribing guidelines/recommendations guided therapy (control intervention).
Key Details
Gender
All
Age Range
12 Years - 17 Years
Study Type
INTERVENTIONAL
Enrollment
452
Start Date
2025-02-11
Completion Date
2027-12
Last Updated
2025-04-27
Healthy Volunteers
No
Conditions
Interventions
Pharmacogenetic-guided dosing
SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
Current prescribing guidelines/recommendations
SSRI dosing based on current prescribing guidelines/recommendations
Locations (1)
University of Calgary
Calgary, Alberta, Canada